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Background: The purpose of this study was to compare endothelial cell counts after 
Descemet’s stripping automated endothelial keratoplasty (DSAEK) and penetrating keratoplasty 
in Asian eyes.
Methods: This was a retrospective study of patients from our prospective Singapore Corneal 
Transplant Study cohort who received corneal transplantation in 2006–2008. We compared 
eyes that underwent DSAEK or penetrating keratoplasty for Fuchs’ endothelial dystrophy or 
pseudophakic and aphakic bullous keratopathy. Clinical data, and donor and recipient charac-
teristics were recorded. Of 241 patients who met our inclusion criteria, 68 underwent DSAEK 
and 173 underwent penetrating keratoplasty. The main outcome measure was endothelial cell 
loss at 1 year. Secondary outcome measures were graft survival and visual outcomes at 1-year 
follow-up.
Results: There were no significant differences in baseline characteristics of patients between 
the treatment groups. Percent endothelial cell loss at 1-year follow-up was greater in 
penetrating keratoplasty eyes (40.9% ± 2.9%) compared with DSAEK eyes (22.4% ± 2.3%; 
P , 0.001). DSAEK-treated eyes had significantly superior uncorrected visual acuity 
(mean difference = 0.42 ± 0.0059; P , 0.001) and best spectacle-corrected visual acuity (mean 
difference = 0.14 ± 0.032; P , 0.001) as compared with penetrating keratoplasty-treated eyes. 
Penetrating keratoplasty-treated eyes had worse astigmatism as compared with DSAEK-treated 
eyes (−3.0 ± 2.1 versus −1.7 ± 0.8; P , 0.001). Graft survival at 1 year was comparable in 
both groups, ie, 66/68 (97.0%) DSAEK-treated eyes versus 158/173 (92.0%) of penetrating 
keratoplasty-treated eyes had clear grafts (P = 0.479).
Conclusion: We report lower percent endothelial cell loss comparing DSAEK and penetrating 
keratoplasty at 1-year follow-up in Asian eyes, with comparable graft survival rates in both 
groups.
Keywords: Descemet’s stripping automated endothelial keratoplasty, endothelial cell count, 
penetrating keratoplasty
Introduction
Corneal transplantation for corneal endothelial diseases is undergoing a paradigm 
shift from penetrating keratoplasty to endothelial keratoplasty.1 Descemet’s stripping 
automated endothelial keratoplasty (DSAEK), which is essentially endothelial ker-
atoplasty that involves donor tissue preparation using an automated microkeratome, 
is rapidly becoming the preferred alternative to conventional penetrating keratoplasty 
for endothelial dysfunction, such as Fuchs’ endothelial keratoplasty and pseudophakic 
bullous keratopathy.2 In the United States, the number of donor corneas for endothelial 
keratoplasty has exponentially increased from 3% (2005) to 33% (2007) and 42.8% 
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in 2009 (Eye Banking Statistical Report 2009, Eye Bank 
Association of America data (http://www.restoresight.org/
donation/statistics.htm).
The advantages of DSAEK over penetrating kerato-
plasty include better tectonic stability, essentially sutureless 
surgery, and faster postoperative visual rehabilitation with 
more predictable refractive changes.3–7 However, early stud-
ies mainly in Caucasian eyes suggest equivalent or higher 
cell loss in DSAEK compared to penetrating keratoplasty 
at 6 months, albeit nonsignificant by 2 years.3,8–12
The main aim of this study was to compare our DSAEK 
results in terms of endothelial cell loss with those of penetrat-
ing keratoplasty with at least 1-year follow-up in Asian eyes 
using our previously described DSAEK technique.13
Materials and methods
We conducted a retrospective study of patients who under-
went DSAEK or penetrating keratoplasty for which the 
surgical indication was either Fuchs’ endothelial dystro-
phy or pseudophakic and aphakic bullous keratopathy in 
2006–2008. We excluded any patients who did not have a 
minimum pos-surgical follow-up of 1 year. Our subjects 
and clinical data were obtained from the ongoing cohort 
of the Singapore Corneal Transplant Study, an audited 
longitudinal prospective study which contains preoperative, 
  intraoperative, and yearly postoperative follow-up clinical 
data.14 This study followed the principles of the Declara-
tion of Helsinki, with ethics approval obtained from our 
institutional review board. A total of 241 patients met our 
inclusion criteria, of whom 68 underwent DSAEK and 
173 underwent penetrating keratoplasty by the five corneal 
surgeons at our center, as well as inclusion of cases which 
were partially performed by corneal fellows in training 
under direct supervision.
We reviewed patient demographics, clinical features, 
and surgical techniques. Our main outcome measure was 
endothelial cell count and the derived percent endothelial cell 
loss at 1 year follow-up. Our secondary outcome measures 
included graft success and visual acuity at 1 year follow-up. 
Visual acuity was measured using the Snellen visual acuity 
chart and we analyzed the results using logarithm of the 
minimum angle of resolution (logMAR) equivalent units, 
including manifest refraction, spherical equivalent, and 
cylindrical error.15 The Singapore Eye Bank provides all 
donor corneas, stored in Optisol™ in cold storage, with 
standard internal guidelines for penetrating keratoplasty and 
DSAEK grafts and we obtained all donor information from 
their database, including donor endothelial cell counts.14 
Preoperative specular microscopy of the donor tissue was 
performed either by certified technicians in an Eye Bank 
Association of   America-certified eye bank or by a certified 
eye bank technician at the Singapore Eye Bank.   Postoperative 
specular microscopy measurements of endothelial cell den-
sity were performed using a noncontact specular microscope 
(Konan Medical Corporation, Hyogo, Japan) at 12 months 
postoperatively, by ophthalmic technicians trained in specular 
microscopy. Calibrations and magnifications were standard-
ized automated measurements with a mean value derived, 
as previously described.16 The incidence of postoperative 
complications was obtained from the Singapore Corneal 
Transplant Study database, which tracks all graft complica-
tions. Graft failure was defined as irreversible loss of optical 
clarity, with the date of onset of corneal clouding selected as 
the time point of graft failure.
Surgical technique
Penetrating keratoplasty surgeries were performed using a 
standard technique based on a Hanna vacuum trephine system 
(Moria Inc, Antony, France). In summary, the recipient cor-
nea was excised using the Hanna trephine. A 0.25–0.50 mm 
oversized donor cornea was then punched out endothelial 
side up and sutured on to the recipient with 10-0 nylon, using 
either an 8-bite, 10-0 nylon double continuous running suture 
or a combination of a single 8-bite 10-0 nylon continuous and 
eight interrupted sutures. Intraoperative astigmatic control 
was achieved using a microscope-mounted keratoscope. 
A bandage contact lens was placed at the end of the surgery, 
and subconjunctival dexamethasone 0.1% (Decadron®; 
Merck and Co, Inc, Rahway, NJ), gentamicin 14 mg/mL 
(Garamycin®; Schering AG, Berlin-Wedding, Germany), and 
cefazolin 50 mg/mL (Ancef®; GlaxoSmithKline, Research 
Triangle Park, NC) was injected.
DSAEK was performed using our previously described 
technique.13,16 Essentially, after Descemet’s stripping under 
air,17 a paracentesis was first made in the peripheral cornea 
opposite the scleral tunnel wound for insertion of Kawai 
intraocular capsulorhexis forceps (Asico, Westmont, IL) or 
Tan DSAEK forceps (Asico).13 A standard anterior chamber 
intraocular lens sheets glide (BD Visitec™) was trimmed 
to 4.5 mm and inserted into the eye through a 5 mm tem-
poral scleral tunnel incision while the anterior chamber 
was maintained via an anterior chamber maintainer with 
a balanced salt solution infusion. An inferior peripheral 
iridectomy was performed through a limbal stab incision. 
The donor was prepared by the surgeon using an automated 
lamellar therapeutic keratoplasty system (ALTK; Moria SA, 
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Antony, France) aiming for a donor cornea of thickness of 
approximately 150 microns. Four preplaced corneal venting 
incisions were made on the recipient cornea. A dispersive 
ophthalmic viscosurgical device (VisCoat®; Alcon Labora-
tories Inc, Hünenberg, Switzerland) was liberally applied 
over the endothelial surface of the donor cornea and on the 
anterior surface of the glide, taking care not to have the oph-
thalmic viscosurgical device on the stromal donor surface. 
The donor cornea was gently inverted, corneal endothelial 
surface-down, onto the ophthalmic viscosurgical device 
covered portion of the glide. Kawai or Tan DSAEK forceps 
were passed through the nasal paracentesis, over the sheets 
glide, and out through the scleral incision, grasping the donor 
cornea stromal edge and pulling the donor cornea through 
the scleral incision, whilst the anterior chamber maintainer 
was infusing balanced salt solution at a medium to slow 
rate. With this technique, a deep chamber was maintained 
throughout the maneuver. A small air bubble was injected 
under the donor cornea with a 30-gauge canula to prevent 
descent of the donor cornea, the sheets glide retracted, and 
the donor cornea was released from the forceps. The scleral 
tunnel was then sutured with three 10/0 nylon interrupted 
sutures, the anterior chamber maintainer was removed 
and the port sutured, the donor was adjusted centrally by 
gentle massage through the cornea surface, and full air 
tamponade was achieved with a large bubble in the ante-
rior chamber for 8 minutes. Following this, some air was 
replaced with balanced salt solution, leaving a smaller air 
bubble approximating the size of the endothelial keratoplasty 
graft in the anterior chamber. Subconjunctival steroid and 
antibiotic injections and a bandage contact lens completed 
the procedure. All patients were examined approximately 
one hour after surgery to ensure air was still present in the 
anterior chamber, and no donor dislocation or pupillary 
block was present. We used similar postoperative medication 
regimens in both groups, ie, Predforte® (prednisolone acetate 
ophthalmic suspension, USP) 1% every 3 hours for 1 week, 
three times a day for 6 months, twice daily for 3 months then 
once a day for up to 1 year.
Statistical analysis
Statistical analysis included descriptive statistics, whereby 
the mean and standard deviation were calculated for the 
continuous variables, while the frequency distribution and 
percentages were used for categorical variables. Comparisons 
between categorical variables were conducted using Fisher’s 
exact tests, whereas the one-way analysis of variance test 
was used for means. Kaplan–Meier survival analysis was 
conducted to determine survival probabilities of penetrating 
keratoplasty and DSAEK groups. The survival period of 
failed grafts was defined as the time between the date of 
surgery and recorded date of survival or failure. The estimate 
of odds ratio and its relative 95% confidence interval was 
calculated. A P value ,0.05 was considered statistically 
significant.
Results
Recipient characteristics
The demographics and clinical characteristics of our study 
cohort are summarized in Table 1. Overall, there were 
more patients whose main surgical indication was bullous 
keratopathy as compared with Fuchs’ dystrophy (153/241, 
63.5%) and more of the patients with bullous keratopathy 
had undergone a penetrating keratoplasty as compared with 
DSAEK (120/173, 69.4% versus 33/68, 48.5%; P = 0.003). 
However, there were no significant differences in demograph-
ics or characteristics of patients with bullous keratopathy or 
Fuchs’ dystrophy between the treatment groups.
Endothelial cell counts
The mean preoperative donor endothelial cell density was 
101 cells/mm2 greater in the DSAEK than in the penetrating 
keratoplasty group (2792 ± 327 versus 2691 ± 360 cells/mm2; 
P = 0.0412). Donor size was significantly larger in patients 
undergoing DSAEK as compared with penetrating kerato-
plasty (mean donor size 8.75 ± 0.49 versus 7.87 ± 0.34 mm; 
P , 0.001). Postoperative endothelial cell density was obtain-
able in 120 eyes (60 DSAEK-treated eyes and 60 penetrating 
keratoplasty-treated eyes) performed at 1-year follow-up. 
In this subanalysis, there were no significant differences in 
baseline characteristics, such as mean recipient age (64 ± 10 
versus 67 ± 11 years; P = 0.08) sex (P = 0.06), race (P = 0.16), 
or diagnosis (51% versus 49% Fuchs’ dystrophy; P = 0.86) 
between the DSAEK and penetrating keratoplasty groups. 
We found that mean endothelial cell density was greater at 
1 year in the DSAEK group as compared with the penetrating 
keratoplasty group (2174 ± 66 versus 1555 ± 76; P = 0.001) 
and overall percentage of endothelial cell loss after 1 year 
was 40.9% ± 2.9% in penetrating keratoplasty-treated and 
22.4% ± 2.3% in DSAEK-treated eyes (P , 0.001). In patients 
with Fuchs’ dystrophy, DSAEK-treated eyes had significantly 
less percentage of endothelial cell loss compared with penetrat-
ing keratoplasty-treated eyes (30 eyes each group, mean percent-
age endothelial cell loss; 20.4% ± 1.4% versus 37.7% ± 2.3%; 
P = 0.001). This was similar to patients with bullous keratopathy 
(30 eyes each group, mean percentage of endothelial cell loss; 
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24.2% ± 2.0% versus 41.8% ± 2.2%; P = 0.002). We also 
compared percentage of endothelial cell loss at 1 year between 
patients with Fuchs’ dystrophy and bullous keratopathy. At 1 
year, the percentage of endothelial cell loss did not differ signifi-
cantly between patients with Fuchs’ dystrophy and those with 
bullous keratopathy for either procedure (39% versus 44% in 
penetrating keratoplasty-treated eyes; P = 0.40; and 20% versus 
24% in DSAEK-treated eyes; P = 0.45).
Visual acuity outcomes at 1 year
In our study cohort, 26 patients had concomitant eye disease, 
which significantly impacted on final visual outcome, while 
17 patients had late graft failure at 1 year. All these patients 
were excluded from our final visual acuity analysis (Table 2). 
We compared the remaining patients (61 DSAEK with 137 
penetrating keratoplasty-treated eyes) with respect to visual 
acuity. Amongst these patients there were fewer patients 
who had Fuchs’ dystrophy in the penetrating keratoplasty 
group (35/61 [57.3%] DSAEK; 51/137 [37.2%] penetrating 
keratoplasty; P = 0.011). Sutures remained in place for all 
penetrating keratoplasty-treated eyes.
Patients who underwent DSAEK had better visual out-
comes at 1 year when compared with penetrating keratoplasty-
treated patients (Table 3). Overall, DSAEK-treated eyes had 
significantly superior uncorrected visual acuity (UCVA) 
and best spectacle-corrected visual acuity (BSCVA) as 
compared with penetrating keratoplasty-treated eyes at 
1 year (mean difference UCVA, 0.42 ± 0.0059; P , 0.001; 
BSCVA, 0.14 ± 0.032; P , 0.001). In addition, there were 
more eyes with BSCVA better than 20/40 in DSAEK-treated 
Table 1 Characteristics of patients (overall, penetrating keratoplasty, and DSAEK)
Characteristics Corneal graft P valuea
Total 
(n = 241)
PK 
(n = 173)
DSAEK 
(n = 68)
Mean age, years (±SD) 67.5 (11.3) 68.4 (10.0) 65.3 (13.7) 0.062
Gender (%)
  Male
  Female
118 (49.0)
123 (51.0)
82 (47.4)
91 (52.6)
36 (52.9)
32 (47.1)
0.476
Race (%)
  Chinese
  Malay
  Indian
  Caucasian
  Others
207 (85.9)
13 (5.4)
3 (1.2)
2 (6.2)
16 (6.6)
162 (93.6)
10 (5.8)
0
0
1 (0.58)
45 (66.2)
3 (4.4)
3 (4.4)
2 (2.9)
15 (22.1)
0.001
Primary indication
  Fuchs’ dystrophy
    Pseudophakic/aphakic  
bullous keratopathy
88 (36.5)
153 (63.5)
53 (30.6)
120 (69.4)
35 (51.5)
33 (48.5)
0.003
Type of surgery
  Graft alone
  Graft + cataract extraction + IOL
  Graft + cataract extraction + ACIOL
  Graft + secondary IOL implant
  Anterior vitrectomy
146 (60.6) 
52 (21.6) 
12 (5.0) 
6 (2.5) 
20 (8.3)
90 (52.0) 
44 (25.3) 
10 (5.8) 
5 (2.9) 
19 (11.0)
56 (82.4) 
8 (11.8) 
2 (3.0) 
1 (1.5) 
1 (1.5)
0.03 
0.02 
0.518 
0.524 
0.004
Visual acuityb (logMAR)
  Preoperative visual acuity (mean, SD) 
  Postoperative UCVA (mean, SD) 
  Postoperative BCVA (mean, SD) 
  Percent change in visual acuity (%, SD)
1.77 (0.76) 
0.64 (0.47) 
0.37 (0.34) 
69.4 (25.1)
1.86 (0.42) 
0.78 (0.50) 
0.42 (0.19) 
68.3 (25.7)
1.56 (0.66) 
0.33 (0.18) 
0.27 (0.17) 
71.8 (23.7)
0.001 
0.001 
0.001 
0.376
Refractive outcomec
  Sphere, diopter (mean, SD) 
  Cylinder, diopter (mean, SD) 
  Spherical equivalent (mean, SD)
+0.17 (2.8) 
−2.6 (1.9) 
−1.3 (3.0)
−0.021 (3.2) 
−3.0 (2.1) 
−1.5 (3.3)
+0.62 (1.8) 
−1.7 (0.81) 
−0.25 (1.8)
0.166 
0.001 
0.001
Percent ECD lossc (%, SD) 31.7 (2.2) 40.0 (2.3) 22.4 (1.8) 0.001
Number of graft failures at 1 yeard (%) 17 (7.1) 15 (8.0) 2 (3.0) 0.118
Notes: aP value from one-way analysis of variance or Chi-square test as appropriate; bnumber of patients with valid visual acuity (n = 198; PK = 137, DSAEK = 61); cnumber 
of patients with valid endothelial cell counts (n = 120; PK = 60, DSAEK = 60); dgraft failure defined as irreversible loss of optical clarity, with the date of onset of corneal 
clouding selected as the time point of graft failure.
Abbreviations: ACIOL, anterior chamber intraocular lens; PK, penetrating keratoplasty; DSAEK, Descemet’s stripping automated endothelial keratoplasty; VA, visual acuity; 
BCVA, best-corrected visual acuity; UCVA, uncorrected visual acuity; ECD, endothelial cell density; SD, standard deviation; IOL, intraocular lens.
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Table 2 Patients excluded from visual outcome analysis
Concomitant  
diseases
PK-treated  
eyes
DSAEK-treated  
eyes
Percent 
(%)
AMD
Macular scar
Advanced glaucoma
Advanced diabetic  
retinopathy
Graft failure at 1 year
Others
2
4
3
2
15
2
3
3
4
2
2
1
11.6
16.3
16.3
9.3
39.5
7.0
Total 28 15 100
Abbreviations:  PK,  penetrating  keratoplasty;  DSAEK,  Descemet’s  stripping 
automated endothelial keratoplasty; AMD, age-related macular degeneration.
Table 3 Outcomes of patients (PK and DSAEK) subdivided into Fuchs’ dystrophy and pseudophakic/aphakic bullous keratopathy
Characteristics Corneal graft P valuea
PK 
(n = 137)
DSAEK 
(n = 61)
Fuchs’ dystrophy (n = 86)
Visual acuityb (logMAR)
  Preoperative visual acuity (mean, SD) 
  Postoperative UCVA (mean, SD) 
  Postoperative BCVA (mean, SD) 
  Percent change in visual acuity (%, SD)
1.29 (0.67) 
0.80 (0.59) 
0.45 (0.36) 
54.1 (43.2)
1.02 (0.56) 
0.37 (0.35) 
0.26 (0.19) 
69.1 (24.5)
0.001 
0.011 
0.003 
0.376
Refractive outcomeb
  Sphere, diopter (mean, SD) 
  Cylinder, diopter (mean, SD) 
  Spherical equivalent (mean, SD)
−0.043 (3.0) 
−2.6 (1.8) 
−1.6 (3.2)
+0.49 (2.1) 
−1.7 (0.84) 
−0.38 (2.1)
0.384 
0.023 
0.052
Pseudophakic/aphakic bullous keratopathy (n = 112)
Visual acuityb (logMAR)
  Preoperative visual acuity (mean, SD) 
  Postoperative UCVA (mean, SD) 
  Postoperative BCVA (mean, SD) 
  Percent change in visual acuity (%, SD)
1.94 (0.43) 
1.15 (0.86) 
0.84 (0.66) 
54.0 (42.3)
1.29 (0.67) 
0.80 (0.59) 
0.44 (0.36) 
54.1 (43.2)
0.001 
0.001 
0.001 
0.982
Refractive outcomeb
  Sphere, diopter (mean, SD) 
  Cylinder, diopter (mean, SD) 
  Spherical equivalent (mean, SD)
+0.024 (2.9) 
−3.2 (2.2) 
−1.3 (3.5)
+0.74 (1.1) 
−1.7 (0.80) 
−0.12 (1.4)
0.320 
0.001 
0.113
Notes:  aP value from one-way analysis of variance or Chi-square test as appropriate;  bnumber of patients with valid visual acuity (n = 198; PK = 137, DSAEK = 61). 
Abbreviations: PK, penetrating keratoplasty; DSAEK, Descemet’s stripping automated endothelial keratoplasty; VA, visual acuity; BCVA, best-corrected visual acuity; 
UCVA, uncorrected visual acuity; SD, standard deviation.
group as compared with the penetrating keratoplasty-treated 
group (67.2% versus 38.7%; P , 0.001). When comparing 
visual outcomes between surgical indications, we found that 
visual outcome was significantly better in eyes with Fuchs’ 
dystrophy for both DSAEK (mean difference BSCVA, 
0.36 ± 0.011; P = 0.002) and penetrating keratoplasty (mean 
difference BSCVA, 0.40 ± 0.0079; P , 0.001).
Refractive outcomes at 1 year
Overall, patients with penetrating keratoplasty-treated 
eyes had higher astigmatism at 1 year as compared with 
DSAEK-treated eyes (−3.0 ± 2.1 versus −1.7 ± 0.8, 
respectively; P , 0.001, Table 1). We also observed this 
difference in patients with Fuchs’ dystrophy (−2.6 ± 1.8 
versus −1.7 ± 0.8; P = 0.023) and bullous keratopathy 
(−3.2 ± 2.2 versus −1.7 ± 0.8; P = 0.001, Table 3). Overall, 
DSAEK-treated eyes were more hyperopic as compared 
with penetrating keratoplasty-treated eyes at 1 year (spheri-
cal equivalent +1.5 ± 3.3 versus −0.25 ± 1.8, respectively; 
P , 0.001).
Graft success
We had one case of primary graft failure in each of the 
DSAEK and penetrating keratoplasty treatment groups (1/68, 
1.5% versus 1/173, 0.5% respectively; P = 0.31). At 1 year, 
66/68 (97.0%) eyes that underwent DSAEK had clear grafts 
while 158/173 (92.0%) of penetrating keratoplasty-treated 
eyes had clear grafts (P = 0.479). There were no significant 
differences in late graft failure between the groups (pen-
etrating keratoplasty 8% versus DSAEK 3%; P = 0.118). 
Reasons for graft failure in the penetrating keratoplasty 
group were infection-related (n = 10) and immune-related 
(n = 5); and for the DSAEK group were immune-related 
(n = 2). The Kaplan–Meier probability of survival at 1 year 
was 95.3% for the penetrating keratoplasty-treated group, 
which decreased to 89.6% at 18 months, while it was 98.4% 
at 1 year and 93.2% for DSAEK cases up to 18 months of 
follow-up (P , 0.001).
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Table 4 Complications of PK and DSAEK within 1-year follow-up
Complications DSAEK 
n (%)
PK 
n (%)
P valuea
Transient elevated IOP  
(.21 mmHg)
20 (29.4) 52 (30.0) 0.929
Epitheliopathy 0 23 (13.3) 0.014
Graft rejection episode 1 (1.5) 11 (6.3) 0.690
Late graft failure 2 (3.0) 15 (8.0) 0.118
Resuture 0 8 (2.9) 0.352
Wound dehiscence 0 4 (2.3) 1.000
Corneal infection 1 (1.5) 2 (1.1) 0.424
Primary graft failure 1 (1.5) 1 (0.5) 0.307
Recurrence of  
primary disease
0 1 (0.5) 1.000
Reactivation of  
herpetic infection
0 1 (0.5) 1.000
Anterior synechiae 0 1 (0.5) 1.000
Graft detachment  
and repositioning
0 0 –
Suprachoroidal hemorrhage 0 0 –
Endophthalmitis 0 0 –
Note: aChi-square of Fisher’s exact test as appropriate.
Abbreviations: IOP, intraocular pressure; PK, penetrating keratoplasty; DSAEK, 
Descemet’s stripping automated endothelial keratoplasty.
Complications
Complications during the 1-year follow-up period were 
recorded according to our Singapore Corneal Transplant 
Study guidelines.14 We scored complications as events and 
made comparisons between the penetrating keratoplasty 
and DSAEK groups (Table 4).18 Epitheliopathy was sig-
nificantly higher in penetrating keratoplasty-treated eyes 
(P = 0.014), while transient episodes of intraocular pres-
sure elevation . 21 mmHg (defined in terms of short-term, 
ie, #3 months use of antiglaucoma medications) were seen in 
20/68 (29.4%) and 52/173 (30.0%) for DSAEK and penetrat-
ing keratoplasty, respectively (P = 0.93). Of note, most of 
these patients (16/20 [80.0%] for DSAEK and 49/52 [94.2%] 
for penetrating keratoplasty) had an underlying history of 
glaucoma (P = 0.07). Only four eyes (three penetrating ker-
atoplasty, one DSAEK) had had trabeculectomy performed 
previously, and there were no significant differences in 
graft outcomes. All eyes with transiently raised intraocular 
pressure were treated successfully with intraocular pressure-
lowering topical and/or systemic medications. One patient 
who underwent DSAEK had an acute graft rejection episode 
successfully treated with topical steroids, as compared with 
11 (6.3%) in the penetrating keratoplasty-treated group. Of 
note, we had no graft dislocations in our DSAEK-treated 
eyes in this series of patients.
Discussion
In this study we found that 1-year percentage of endothelial 
cell loss and visual outcomes were superior in DSAEK-treated 
eyes as compared with penetrating keratoplasty-treated eyes 
from the same study cohort, which confirms the results of 
our preliminary study on DSAEK in Asian eyes.16 This is in 
contrast with reports in the literature that DSAEK has greater 
endothelial cell loss compared with penetrating keratoplasty, 
but few of these studies reported data on endothelial cell 
loss beyond 12 months of follow-up and none were directly 
compared with penetrating keratoplasty from the same 
study cohort.3,8–12 One study compared subjects from their 
prospective trial on DSAEK with a separate study on pen-
etrating keratoplasty from the Specular Microscopy Ancillary 
Study cohort.19 Another study found that 1-year endothelial 
cell density was lower with DSAEK compared with penetrat-
ing keratoplasty albeit but the difference was not statistically 
significant.20 This led to the conclusion in a recent review 
article that there is currently insufficient evidence to conclude 
whether endothelial cell loss is greater in DSAEK.21 The 
results from this study are encouraging because our endothe-
lial cell loss at 1 year (22.4% ± 2.3%) using a sheets glide 
nonfolding technique was comparable with other non-folding 
techniques, and we were able to show less endothelial cell 
loss comparable with penetrating keratoplasty from a same 
cohort of patients. Although our endothelial cell loss is less 
than that using a taco-folding technique,22 longer follow-up 
is required to confirm if we have a similar endothelial cell 
loss trend. Another advantage of performing DSAEK over 
penetrating keratoplasty is the ability to use a larger donor 
size, and thus transplant more endothelial cells.4 In our study, 
the mean donor size was 10% larger and endothelial cell den-
sity was greater in the DSAEK group than in the penetrating 
keratoplasty group (P , 0.001).
The percentage endothelial cell loss, visual outcomes, 
and astigmatism in eyes with Fuchs’ dystrophy and bullous 
keratopathy treated with penetrating keratoplasty in our 
study of Asian eyes were comparable with those of previ-
ous reports in Caucasian eyes.3,23–25 However, it may not 
be useful to compare visual outcomes at 1 year between 
DSAEK and penetrating keratoplasty due to the longer visual 
rehabilitation and use of sutures in penetrating keratoplasty, 
thus it was only a secondary outcome measure. Nonetheless, 
in our study, DSAEK had better postoperative UCVA and 
BSCVA as compared with penetrating keratoplasty, which 
was also found in Caucasian eyes but with fewer eyes (20 in 
each group).3,20 While this is somewhat expected, our results 
confirm that visual rehabilitation takes much longer after 
penetrating keratoplasty, even when comparing BSCVA 
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at 1 year follow-up. In our study cohort there was a higher 
proportion of pseudophakic eyes amongst patients who had 
undergone DSAEK for Fuchs’ dystrophy. This is because 
we adhere to the general policy that lens removal prior to 
DSAEK obviates the risk of subsequent cataract formation 
and also creates more space in the anterior chamber dur-
ing DSAEK surgery. Moreover, more of the penetrating 
keratoplasty-treated eyes had complicated surgeries that 
required anterior vitrectomy and anterior chamber intraocular 
lens insertion. These factors could contribute to the poorer 
visual outcome and lower endothelial cell counts in the 
penetrating keratoplasty-treated group.
The main limitations of our study are due to its retrospective 
nature. Although our patients differed in their characteristics, 
such as demographics and phakic status, we matched subjects 
in each group for donor and recipient characteristics. We 
acknowledge that case selection between DSAEK and pen-
etrating keratoplasty was dependent on surgeon choice, and 
that more severe or advanced cases of corneal decompensation 
were likely to have received penetrating keratoplasty surgery. 
However, we do routinely attempt DSAEK in severe cases of 
bullous keratopathy, as long as there is only moderate anterior 
stromal scarring present. This may have affected our postop-
erative visual outcome comparisons, although this would have 
minimal effect on differences in endothelial cell loss postop-
eratively between DSAEK and penetrating keratoplasty. Our 
study also had a limited follow-up period of 1 year in order 
to compare graft survival and record reliable endothelial cell 
count data, which was only obtained in 120 eyes. However, we 
analyzed eyes from each group matched for surgical indication 
to minimize selection bias and there were no significant baseline 
differences in each group. Nevertheless, due to the inherent suc-
cess of DSAEK, it would be challenging and unethical in our 
institution to conduct a randomized controlled study given the 
clinical advantages of DSAEK over penetrating keratoplasty, 
hence a historical cohort of penetrating keratoplasty cases in 
the same population group using the same postoperative regime 
provided the best comparative cohort.
Conclusion
We found that performing DSAEK using the described tech-
nique in Asian eyes resulted in a lower 1-year endothelial 
percent cell loss as compared with penetrating keratoplasty 
for patients with Fuchs’ dystrophy and bullous keratopathy. 
Graft survival was comparable in both groups at 1-year 
follow-up, although visual outcomes were superior in the 
DSAEK group with fewer complications. Longer follow-up 
will provide more data on endothelial cell loss with these 
two techniques. Improvements in donor insertion devices 
may reduce the initial ECC loss further and improve long-
term ECC outcomes.26
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